311 related articles for article (PubMed ID: 15720190)
1. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
2. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
4. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
5. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
6. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
7. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
[TBL] [Abstract][Full Text] [Related]
8. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
9. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
10. Targeting the p53-MDM2 interaction to treat cancer.
Klein C; Vassilev LT
Br J Cancer; 2004 Oct; 91(8):1415-9. PubMed ID: 15452548
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
12. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors of p53/MDM2 interaction.
Fotouhi N; Graves B
Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
15. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
17. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
18. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
19. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
20. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]